ICCC

Business Context and Reporting Period

Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: ImmuCell operates in a single segment focused on the development, acquisition, manufacture, and sale of products to improve the health and productivity of cows for the dairy and beef industries. Key products include First Defense® and Wipe Out® Dairy Wipes. The company is heavily dependent on the successful development of new products, notably Mast Out® under a strategic agreement with Pfizer Animal Health.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 29% ($355,000) year-over-year. Product sales rose 17% to $1.43 million, driven by a 16% increase in First Defense® sales and a 54% increase in Wipe Out® Dairy Wipes sales (offsetting domestic declines with new foreign sales).
• New Revenue Streams: The company recognized $123,288 in revenue from the sale of technology rights and $37,631 in grant income, categories that had zero revenue in Q1 2004. These relate to a $1.5 million upfront payment from Pfizer and a grant for human health research.
• Profitability: Net income increased 51% to $259,474. Net operating income rose to $413,107 from $279,421.
• Expense Increases: Research and development (R&D) expenses increased 42% to $314,186. This was primarily due to $80,000 in amortization of an intangible asset related to the Mast Out® license buyout from Nutrition 21, Inc.
• Liquidity: Cash and cash equivalents increased by $258,856 during the quarter. Total assets grew to $9.85 million.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Pfizer Agreement: Under the December 2004 agreement for Mast Out®, the company is eligible for additional milestone payments: $250,000 in late 2005 for a patent filing and $500,000 in early 2006 for manufacturing transfer. Future milestones depend on clinical trials and regulatory approvals.
• Capital Resources: Management believes current capital resources are sufficient to meet working capital requirements for at least the next 12 months.
• Product Pipeline: The company is exploring new applications for Nisin technology, including treatments for mastitis in dry cows and scours in calves. A new distribution agreement with TCS Biosciences Ltd. was signed in April 2005 for the Crypto-Scan® water diagnostic test.

Risks and Contingencies

• Regulatory Risk: Continued sales of First Defense® depend on USDA approval of the "Reference Standard." Failure to requalify could require costly clinical studies.
• Market Risk: The U.S. dairy industry faces economic pressure, forcing small producers out of business, which impacts the customer base. Sales are also subject to seasonality.
• Operational Risk: The company relies on a single manufacturing facility in Portland, Maine, and a small workforce (~24 employees). Disruption at this facility or loss of key personnel could adversely affect operations.
• Dependency: Future growth is heavily dependent on the successful development of Mast Out®, where Pfizer controls development and commercialization and retains the right to terminate the license.

Investor Verification Checklist

• Pfizer Milestone Timing: Verify the specific dates and conditions for the $250,000 (late 2005) and $500,000 (early 2006) milestone payments.
• Revenue Recognition Policy: Confirm the amortization schedule for the $1.5 million Pfizer upfront payment (currently recognized through Dec 31, 2007) and the impact of any changes in development timelines.
• Customer Concentration: Note that Walco International, Inc. accounted for 18% of product sales and 17% of accounts receivable in Q1 2005.
• Regulatory Status: Monitor USDA communications regarding the requalification of the First Defense® Reference Standard.
• Stock-Based Compensation: Review the pro forma impact of FAS 123R (effective Jan 1, 2006), which would reduce reported net income by approximately $3,173 for the quarter.